Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

HLA and KIR polymorphism among patients with chronic hepatitis C (CROSBI ID 718671)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Stingl Jankovic, Katarina ; Jukic, Lucija ; Burek Kamenaric, Marija ; Maskalan, Marija ; Grubic, Zorana ; Zunec, Renata HLA and KIR polymorphism among patients with chronic hepatitis C / Marsh, Steven G. E. (ur.). John Wiley & Sons, 2022. str. 416-550 doi: 10.1111/tan.14606

Podaci o odgovornosti

Stingl Jankovic, Katarina ; Jukic, Lucija ; Burek Kamenaric, Marija ; Maskalan, Marija ; Grubic, Zorana ; Zunec, Renata

engleski

HLA and KIR polymorphism among patients with chronic hepatitis C

The HLA and KIR complexes, as two major factors of immune system, influence the course of numerous infectious diseases. The of the study was to investigate the association of these genetic systems' polymorphism with hepatitis C virus (HCV) infection. HLA class I and II genes (HLA-A, -B, - C, -DRB1 and -DQB1) as well as KIR genes (KIR2DL1, KIR2DL2, KIR2DL3, KIR2DL4, KIR2DL5, KIR2DS1, KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1, KIR3DL2, KIR3DL3, and KIR3DS1)and pseudogenes (KIR2DP1, KIR3DP1) were analyzed for 59 patients listed for liver transplantation with a ETRL code D04 (Cirrhosis - Virus C related cirrhosis)and 214 healthy control individuals using high resolution molecular HLA typing methods. Comparison of allele frequencies revealed a significantly increased frequency among patients for HLA-DRB1*15:01 and *15:02 alleles(P=0.048, P=0.042, respectively), HLA- DRB1*15 specificity (P=0.007) ; and HLA- DQB1*06:01 allele(P=0.042). Two-locus haplotype analysis demonstrated an increased occurrence of following haplotypes among patients: HLA- A*01:01~B*07:02 (P=0.033), HLA-A*03:01~B*35:01 (P=0.021), HLA-B*35:01~C*04:01(P=0.031), HLA- B*37:01~C*06:02 (P=0.033), HLA-B*51:01~C*12:03 (P=0.010), HLA-B*35:01~DRB1*16:01(P=0.010), HLA- B*44:02~DRB1*13:02 (P=0.010), HLA- B*51:01~DRB1*08:01 (P=0.010), HLA- B*52:01~DRB1*15:02 (P=0.010), HLA- B*18:01~DRB1*15:01 (P=0.003), HLA- DRB1*15:02~DQB1*06:01(P=0.003), HLA- DRB1*15:01~DQB1*05:02 (P=0.009). Among KIR genes, only the increase of the KIR2DS4 deletion variant frequency among patients was significant (P=0.0331). None of the observed differences retained statistical significance after correction of P value for multiple comparisons. In conclusion, although numerous observed differences in distribution of HLA and KIR polymorphisms between HCV patients and controls suggest a possible role of these systems in HCV infection. Future studies should include a larger number of patients in order to reliably determine their importance for this viral infection.

HLA, KIR, chronic hepatitis C

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

416-550.

2022.

objavljeno

10.1111/tan.14606

Podaci o matičnoj publikaciji

Marsh, Steven G. E.

John Wiley & Sons

2059-2302

Podaci o skupu

36th European Immunogenetics and Histocompatibility Conference

poster

17.05.2022-20.05.2022

Amsterdam, Nizozemska

Povezanost rada

Biologija, Kliničke medicinske znanosti

Poveznice
Indeksiranost